Does Doravirine Lamivudine And Tenofovir Disoproxil Fumarate Interact with Rifabutin?
CDI records a major classification for Doravirine Lamivudine And Tenofovir Disoproxil Fumarate and Rifabutin. The stored summary is: Co-administration decreases doravirine plasma concentrations. If co-administered, one tablet of doravirine should be taken approximately 12 hours after the dose of DELSTRIGO. The mechanism involves cyp3a induction. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Major
- Doravirine Lamivudine And Tenofovir Disoproxil Fumarate Class
- Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
- Rifabutin Class
- Rifamycin Antimycobacterial
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
CYP3A induction
What To Tell Your Doctor or Pharmacist
If you are taking Doravirine Lamivudine And Tenofovir Disoproxil Fumarate and your doctor is considering prescribing Rifabutin (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider